Edwards Lifesciences Co. (NYSE:EW) VP Sells $1,212,624.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the sale, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Edwards Lifesciences Stock Down 0.5 %

EW opened at $84.23 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The business has a 50 day simple moving average of $90.18 and a 200-day simple moving average of $79.19. The stock has a market capitalization of $50.70 billion, a P/E ratio of 36.31, a P/E/G ratio of 3.62 and a beta of 1.05. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on EW. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Stifel Nicolaus upped their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. Piper Sandler upped their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a research report on Friday, April 26th. Oppenheimer upped their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, March 18th. Finally, StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Monday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $92.71.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of EW. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth $34,000. Riverview Trust Co purchased a new position in Edwards Lifesciences during the first quarter worth $34,000. Pingora Partners LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth $38,000. Finally, Operose Advisors LLC increased its position in Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after buying an additional 452 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.